Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-10-24
|
BGB324 and pembrolizumab Company: |
non-small cell lung cancer (NSCLC) |
2 |
BergenBio (Norway) |
Cancer - Oncology |
2017-10-23
|
JNJ-4178 (AL-335) simeprevir, odalasvir |
chronic Hepatitis C Virus (HCV) genotype 1-6 infection, with and without cirrhosis |
2b |
Janssen Research & Development, a J&J company (USA - NJ) Medivir (Sweden) |
Infectious diseases |
2017-10-23
|
TG1050 (therapeutic vaccine) |
chronic hepatitis B |
1-1b |
Transgene (France) |
Infectious diseases |
2017-10-19
|
FR104 |
rheumatoid arthritis, psoriasis |
preclinical |
Effimune (France) now OSE Immunotherapeutics (France) |
Autoimmune diseases – Dermatological diseases - Inflammatory diseases - Rheumatic diseases |
2017-10-19
|
ATA188 |
progressive or relapsing-remitting multiple sclerosis |
1 |
Atara Biotherapeutics (USA - CA) |
Autoimmune diseases - Neurodegenerative diseases* |
2017-10-19
|
DV281 |
non-small cell lung cancer (NSCLC) |
1b |
Dynavax (USA - CA) |
Cancer - Oncology |
2017-10-19
|
GED-0301 (mongersen) |
Crohn disease |
3 |
Celgene (USA - NJ) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2017-10-19
|
bemcentinib (BGB324) |
previously treated, locally advanced and unresectable or metastatic triple-negative breast cancer (TNBC) or triple negative inflammatory breast cancer (TN-IBC) |
2 |
BergenBio (Norway) |
Cancer - Oncology |
2017-10-18
|
BMN 111 (vosoritide) |
achondroplasia |
2 |
Biomarin Pharmaceutical (USA - CA) |
Rare diseases - Genetic diseases |
2017-10-18
|
PCM-075 (1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt) and Zytiga® (abiraterone acetate) |
metastatic prostate cancer |
preclinical |
Trovagene (USA - CA) |
Cancer - Oncology |
2017-10-18
|
PV-10 and pembrolizumab |
melanoma |
1b-2 |
Provectus Pharmaceuticals (USA - TN) |
Cancer - Oncology |
2017-10-18
|
BMN 270 (valoctocogene roxaparvovec) |
hemophilia A |
3 |
Biomarin Pharmaceutical (USA - CA) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-10-18
|
BMN 290 |
Friedreich's Ataxia |
|
Biomarin Pharmaceutical (USA - CA) |
Rare diseases - Neurodegenerative diseases |
2017-10-18
|
AMT-130 (adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene) |
Huntington's Disease |
preclinical |
Uniqure (The Netherlands) |
Rare diseases - Genetic diseases - Neurodegenerative diseases |
2017-10-17
|
VXM10 |
|
preclinical |
Vaximm (Germany) |
Cancer - Oncology |
2017-10-12
|
AVR-RD-01 |
Fabry disease |
1-2 |
Avrobio (USA - MA) |
Rare diseases - Genetic diseases - Lysosomal diseases |
2017-10-11
|
HORA – PDE6B |
retinitis pigmentosa due to a mutation in the PDE6B gene |
1-2 |
Horama (France) |
Rare diseases - Genetic diseases - Ophtalmological diseases |
2017-10-09
|
THR-317 |
diabetic macular edema, diabetic retinopathy |
preclinical |
Thrombogenics (Belgium) |
Ophtalmological diseases |
2017-10-06
|
omadaycline |
acute bacterial skin and skin structure infections (ABSSSI) |
3 |
Paratek Pharmaceuticals (USA - MA) |
Infectious diseases |
2017-10-02
|
Effi-DEM |
|
preclinical |
OSE Immunotherapeutics (France) |
Cancer - Oncology |